HomeAustraliaBrandon Capital Holds First Close of Sixth Fund, at US$180M

Brandon Capital Holds First Close of Sixth Fund, at US$180M


Brandon Capital, a Melbourne, Australia-based life sciences venture capital firm, announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at US$180M.

Limited Partners in Fund VI included Australian superannuation (pension) funds, and new investors. The vehicle remains open, with ongoing discussions with potential investors both locally and internationally. 

This new fund will support the growth of Australian and New Zealand life sciences startups and growth companies, and expand its international presence, particularly in the UK, Europe, and the United States. The firm also provides support, management, and investment to propel portfolio companies through their early growth stages.

Brandon Capital’s strategy focuses on early-stage innovations with strong scientific and commercial potential. To date, the firm has raised over A$1 Billion across five previous Funds and has completed more than 60 investments in new therapeutic, medical device, and healthtech companies, with numerous notable successful exits. 

Led by Chris Nave, Managing Partner, Brandon Capital is a life sciences venture capital firm providing a model that includes proprietary deal flow through Brandon BioCatalyst and a corporate support services structure that enables portfolio companies to focus on research commercialisation. It has 25 active companies in its portfolio.

The firm operates from offices in Australia, New Zealand, the United Kingdom and the United States.